VIVUS Company Profile (NASDAQ:VVUS)

About VIVUS

VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: VVUS
  • CUSIP: 92855110
Key Metrics:
  • Previous Close: $1.08
  • 50 Day Moving Average: $1.15
  • 200 Day Moving Average: $1.15
  • 52-Week Range: $104,843,000.00 - $0.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.32
  • P/E Growth: -15.00
  • Market Cap: $114.28M
  • Outstanding Shares: 104,843,000
  • Beta: 1.29
Profitability:
  • Net Margins: -78.63%
  • Return on Assets: -16.44%
Debt:
  • Debt-to-Equity Ratio: -6.03%
  • Current Ratio: 2.71%
  • Quick Ratio: 2.61%
Additional Links:
Companies Related to VIVUS:

Analyst Ratings

Consensus Ratings for VIVUS (NASDAQ:VVUS) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $1.90 (74.31% upside)

Analysts' Ratings History for VIVUS (NASDAQ:VVUS)
Show:
DateFirmActionRatingPrice TargetDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80View Rating Details
5/4/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for VIVUS (NASDAQ:VVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for VIVUS (NASDAQ:VVUS)
Current Year EPS Consensus Estimate: $-0.09 EPS
Next Year EPS Consensus Estimate: $-0.47 EPS

Dividends

Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for VIVUS (NASDAQ:VVUS)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 34.82%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.19View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.80View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.40View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.13View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for VIVUS (NASDAQ:VVUS)
DateHeadline
News IconStock Tracker: Earnings & Estimates for VIVUS, Inc. (NASDAQ:VVUS) - Aiken Advocate (NASDAQ:VVUS)
aikenadvocate.com - February 17 at 7:00 AM
News IconSignal Watch: Checking the Numbers for VIVUS Inc. (VVUS) - Rives Journal (NASDAQ:VVUS)
rivesjournal.com - February 14 at 3:52 PM
News IconFollowing the Numbers: VIVUS Inc. (VVUS) - Rives Journal (NASDAQ:VVUS)
rivesjournal.com - February 8 at 1:40 AM
News IconWhat are the Technical Charts Saying About VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - February 2 at 6:43 AM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at VIVUS, Inc. (NASDAQ:VVUS) - Nelson Research (NASDAQ:VVUS)
nelsonobserver.com - February 1 at 7:22 AM
News IconGrowth Story Unfolding for VIVUS, Inc. (NASDAQ:VVUS) | Prospect ... - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 31 at 2:18 AM
News IconIs This Stock Capable of a Bull Run: VIVUS, Inc. (NASDAQ:VVUS) - Nelson Research (NASDAQ:VVUS)
nelsonobserver.com - January 30 at 4:16 PM
News IconCalibrating the Trade: Watching Technicals on Shares of VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 30 at 4:16 PM
News IconCan This Stock Gain Any Traction: VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 30 at 4:16 PM
News IconVolatility Watch on Shares of VIVUS, Inc. (NASDAQ:VVUS) - The Tribune (NASDAQ:VVUS)
lakecitytribune.com - January 27 at 3:50 PM
News IconTracking Williams %R for VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 27 at 3:50 PM
News IconMeasuring the Levels on Shares of VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 27 at 3:50 PM
News IconDelving into Shares of VIVUS, Inc. (NASDAQ:VVUS) | Prospect Journal - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 25 at 9:29 PM
News IconTrading Views: Checking the Numbers for VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 25 at 9:29 PM
News IconEnlivened Volatility Spotted in Shares of VIVUS, Inc. (NASDAQ:VVUS) - Wall Street Beacon (NASDAQ:VVUS)
wsbeacon.com - January 25 at 9:29 PM
News IconEquity Rundown: RSI and CCI Check on VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 24 at 3:25 PM
News IconTrading Ledger: Keeping an Eye on VIVUS, Inc. (NASDAQ:VVUS) - The Tribune (NASDAQ:VVUS)
lakecitytribune.com - January 24 at 3:25 PM
News IconVivus Inc VVUS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:VVUS)
www.bioportfolio.com - January 24 at 2:35 AM
News IconPeering into Recent Action from VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 20 at 8:39 PM
News IconShares in View: VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 20 at 3:36 PM
News IconTrading Scope: Indicator Review for VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 19 at 4:03 PM
News IconCan This Stock Price Climb The Ladder: VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 19 at 4:03 PM
News IconEarnings Take Center Stage; Analysts Weighing in on VIVUS, Inc. (NASDAQ:VVUS) - Aiken Advocate (NASDAQ:VVUS)
aikenadvocate.com - January 19 at 7:22 AM
4-traders.com logoVIVUS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:VVUS)
www.4-traders.com - January 17 at 8:52 PM
biz.yahoo.com logoVIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:VVUS)
biz.yahoo.com - January 17 at 8:52 PM
News IconTrading Roundup: Checking Technicals for VIVUS Inc. (VVUS) - Sherwood Daily (NASDAQ:VVUS)
sherwooddaily.com - January 17 at 3:50 PM
News IconWill The Needle Move For VIVUS, Inc. (NASDAQ:VVUS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VVUS)
wsbeacon.com - January 17 at 3:50 PM
News IconHoning in on Shares of VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 17 at 3:50 PM
News IconIs This a Sensible Stock at Current Levels: VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 13 at 5:54 AM
News IconAre Institutions Jumping Ship on VIVUS, Inc. (NASDAQ:VVUS) - Wall Street Beacon (NASDAQ:VVUS)
wsbeacon.com - January 13 at 5:54 AM
News IconIs the Needle Ready to Move for VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 10 at 4:05 PM
marketexclusive.com logoVIVUS,INC. (NASDAQ:VVUS) Files An 8-K Other Events - Market Exclusive (NASDAQ:VVUS)
marketexclusive.com - January 10 at 4:05 PM
biz.yahoo.com logoVIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:VVUS)
biz.yahoo.com - January 10 at 4:05 PM
streetinsider.com logoVIVUS (VVUS) Acquires Tacrolimus and Ascomycin Rights from Selten Pharma for PAH - StreetInsider.com (NASDAQ:VVUS)
www.streetinsider.com - January 10 at 1:59 AM
News IconIs the Needle Ready to Move on VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 10 at 1:59 AM
biz.yahoo.com logoVIVUS INC Files SEC form 8-K, Other Events (NASDAQ:VVUS)
us.rd.yahoo.com - January 9 at 8:57 PM
streetinsider.com logoVIVUS (VVUS) Acquires Tacrolimus and Ascomycin Rights from Selten Pharma for PAH (NASDAQ:VVUS)
www.streetinsider.com - January 9 at 3:55 PM
marketexclusive.com logoVIVUS,INC. (NASDAQ:VVUS) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:VVUS)
marketexclusive.com - January 9 at 3:55 PM
finance.yahoo.com logoVIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH) (NASDAQ:VVUS)
finance.yahoo.com - January 9 at 3:55 PM
finance.yahoo.com logo9:01 am Vivus acquires Selten Pharma's rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary Arterial Hypertension and related vascular diseases; terms not disclosed (NASDAQ:VVUS)
finance.yahoo.com - January 9 at 3:55 PM
biz.yahoo.com logoVIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme (NASDAQ:VVUS)
biz.yahoo.com - January 9 at 3:55 PM
marketexclusive.com logoInsider Trading Activity VIVUS, Inc. (NASDAQ:VVUS) – Insider Sold 13,790 shares of Stock (NASDAQ:VVUS)
marketexclusive.com - January 6 at 6:32 AM
News IconNear-Term, Can This Stock Move the Needle: VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 4 at 4:25 PM
News IconCan This Stock Gain Traction: VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - January 2 at 3:39 PM
News IconShould Farsighted Investors Pay Attention to VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - December 30 at 12:15 AM
News IconA Look at this Riveting Stock: VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - December 28 at 8:19 AM
capitalcube.com logoETFs with exposure to VIVUS, Inc. : December 27, 2016 (NASDAQ:VVUS)
www.capitalcube.com - December 27 at 8:14 PM
News IconReady for an Upsurge? Analysts Chime in on VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - December 26 at 7:42 PM
News IconPrepping for a Big Move? Share Update on VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - December 24 at 1:52 AM
News IconPrimed for Breakout or Bust? A look at VIVUS, Inc. (NASDAQ:VVUS) - Prospect Journal (NASDAQ:VVUS)
prospectjournal.com - December 21 at 3:46 PM

Social

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

Where is VIVUS's stock going? Where will VIVUS's stock price be in 2017?

4 brokerages have issued 1 year price targets for VIVUS's shares. Their predictions range from $1.00 to $2.80. On average, they anticipate VIVUS's share price to reach $1.90 in the next year.

When will VIVUS announce their earnings?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

Who owns VIVUS stock?

VIVUS's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.18%), Sarissa Capital Management LP (2.46%), Oxford Asset Management (0.32%), Menta Capital LLC (0.28%) and State Street Corp (0.10%). Company insiders that own VIVUS stock include John L Slebir, North Tide Capital, Llc and Santosh T Varghese.

Who sold VIVUS stock? Who is selling VIVUS stock?

VIVUS's stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC. Company insiders that have sold VIVUS stock in the last year include North Tide Capital, Llc and Santosh T Varghese.

Who bought VIVUS stock? Who is buying VIVUS stock?

VIVUS's stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Renaissance Technologies LLC, Oxford Asset Management and State Street Corp.

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of VIVUS stock cost?

One share of VIVUS stock can currently be purchased for approximately $1.09.

VIVUS (NASDAQ:VVUS) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Earnings History Chart

Earnings by Quarter for VIVUS (NASDAQ:VVUS)

Dividend History Chart

Dividend Payments by Quarter for VIVUS (NASDAQ:VVUS)

Last Updated on 2/20/2017 by MarketBeat.com Staff